Last checked at 
Physiomics PLC - London-based mathematical modelling company that supports oncology drug development - Has been awarded a further contract by existing client Merck KGaA involving pre-clinical and clinical modelling and simulation of anti-cancer regimens involving combinations of DNA damage and repair agents. Follows on previous Merck-commissioned projects. Expects the contract award to be completed over the next three months.
Physiomics Chief Executive Officer Jim Millen says: "We are pleased that this longstanding client has once again chosen Physiomics as a partner for outsourced modelling. We look forward to the possibility of further projects with Merck during the current financial year."
Current stock price: 0.98 pence, up 0.4%
12-month change: down 61%
By Greg Rosenvinge, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
